Abstract
Keloid scars represent a significant therapeutic challenge in dermatology due to their invasive growth and high recurrence rates. This review explores the critical roles of gelatinases—specifically Matrix Metalloproteinase-2 (MMP-2) and Matrix Metalloproteinase-9 (MMP-9)—in the dysregulation of the extracellular matrix (ECM) that characterizes keloid formation. By synthesizing current molecular evidence, the review highlights how various signaling cascades, including TGF-β1/Smad, PI3K/AKT, and LncRNA-mediated pathways, converge to drive excessive collagen deposition and fibroblast migration. Understanding these intricate interactions offers promising opportunities for developing targeted therapeutic interventions.
The Challenge of Keloid Scars
Keloids are a prototypical form of aberrant wound healing where scar tissue extends beyond the original injury boundaries. Unlike typical scars, keloids cause physical pain, persistent itching (pruritus), and significant psychological distress. Their resistance to standard treatments, such as surgical excision or corticosteroid injections, stems from a fundamental biological "glitch": the uncontrolled accumulation of the extracellular matrix (ECM), primarily collagen.
Molecular Mechanisms of Keloid Formation
The core of keloid pathogenesis lies in the loss of ECM homeostasis. Matrix metalloproteinases (MMPs) are enzymes responsible for remodeling and degrading the ECM during normal healing. However, in keloids, the regulation of gelatinases (MMP-2 and MMP-9) becomes severely disrupted.
Key Signaling Cascades
Several regulatory axes have been identified as primary drivers of this dysregulation:
- The TGF-β1/Smad Pathway: While TGF-β1 is a known promoter of fibrosis, its relationship with MMPs is complex and context-dependent. It often upregulates MMPs to facilitate fibroblast invasion into surrounding healthy tissue.
- The PI3K/AKT Axis and miR-188-5p: The microRNA miR-188-5p acts as a natural "brake" by suppressing the PI3K/AKT pathway, which normally promotes MMP expression. In keloid tissues, this inhibitory mechanism is frequently downregulated, leading to overactive signaling.
- LncRNA-ZNF252P-AS1: This long non-coding RNA functions as a molecular "sponge" for miR-15b-5p. By sequestering this microRNA, it indirectly promotes the upregulation of MMP-2 and MMP-9 via the BTF3/JAK2/STAT3 pathway, enhancing fibroblast migration.
- Platelet Lysate (PL) Risks: Although used in some regenerative therapies, PL can inadvertently promote keloid formation by activating the p38 and ERK1/2 pathways, which significantly increase MMP-9 levels.
Clinical Insights and Therapeutic Potential
Research confirms that MMP-2 and MMP-9 are significantly overexpressed at the "invasive edge" of keloid scars. This spatial distribution correlates with the clinical behavior of keloids growing into adjacent skin.
Current treatments show a direct link between clinical success and MMP modulation. For instance, 5-fluorouracil (5-FU) and cryotherapy have been shown to reduce MMP-9 levels, correlating with decreased scar volume. Furthermore, experimental inhibition of the JAK2/STAT3 pathway has demonstrated the ability to decrease both gelatinase levels and Type I collagen synthesis, marking it as a high-priority target for future drug development.
Future Directions
Despite these advances, several hurdles remain. The lack of animal models that accurately replicate human keloid pathology limits the translation of laboratory findings. Additionally, the "double-edged sword" nature of MMP-9—which can both degrade collagen and promote invasion—requires more nuanced, stage-specific research. Future strategies may focus on advanced delivery systems, such as nanoparticles or liposomes, to effectively penetrate the dense, poorly vascularized tissue of established keloids.
Summary updated